Amendment: SEC Form SC 13G/A filed by RAPT Therapeutics Inc.
$RAPT
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/27/2025 | $70.00 | Buy | Guggenheim |
| 10/20/2025 | $55.00 | Neutral → Overweight | Analyst |
| 10/13/2025 | $35.00 | Overweight | Barclays |
| 9/26/2025 | $37.00 | Market Perform → Outperform | Leerink Partners |
| 7/30/2025 | $14.00 | Underweight → Neutral | Analyst |
| 5/22/2025 | $6.00 | Buy | H.C. Wainwright |
| 12/26/2024 | $10.00 | Neutral → Buy | H.C. Wainwright |
| 11/13/2024 | $7.00 → $2.00 | Buy → Hold | Stifel |
Guggenheim initiated coverage of RAPT Therapeutics with a rating of Buy and set a new price target of $70.00
Analyst upgraded RAPT Therapeutics from Neutral to Overweight and set a new price target of $55.00
Barclays initiated coverage of RAPT Therapeutics with a rating of Overweight and set a new price target of $35.00
4 - RAPT Therapeutics, Inc. (0001673772) (Issuer)
3 - RAPT Therapeutics, Inc. (0001673772) (Issuer)
4 - RAPT Therapeutics, Inc. (0001673772) (Issuer)
SCHEDULE 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)
SCHEDULE 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)
SCHEDULE 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)
- Initiated prestIgE Phase 2b trial of ozureprubart in food allergy - Announced positive topline data from Phase 2 trial in chronic spontaneous urticaria; results showed ozureprubart at both Q8W and Q12W dosing had comparable efficacy and safety to omalizumab at Q4W dosing - Completed $250 million public offering to strengthen balance sheet SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT) ("RAPT" or the "Company"), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial re
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in November: Guggenheim's 2nd Annual Healthcare Innovation Conference – Fireside chat on Tuesday, November 11, 2025 at 3:30 p.m. ET Stifel 2025 Healthcare Conference – Fireside chat on Wednesday, November 12, 2025 at 2:40 p.m. ET TD Cowen Virtual Immunology & Inflammation Summit – Fire
Trial initiation in food allergy follows promising results in Phase 2 trial in chronic spontaneous urticaria, another IgE-driven conditionRAPT seeks to develop a differentiated anti-IgE therapy for the many patients with food allergies SOUTH SAN FRANCISCO, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that it has initiated the randomized, double-blind, placebo-controlled prestIgE Phase 2b clinical trial of ozureprubart (formerly RPT904) in IgE
SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Scott Braunstein, M.D., and Ashley Dombkowski, Ph.D., to its board of directors. Dr. Braunstein was appointed as a member of the Audit Committee of the Board and Dr. Dombkowski was appointed as a member of the Nominating and Corporate Governance Committee of the Board. The company's lead product candidate RPT904, is a novel, half-life extended monoclonal antibod
SOUTH SAN FRANCISCO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development to oversee the development of RPT904, a novel, half-life extended monoclonal antibody designed to bind free human immunoglobin E ("IgE"), a key driver of several allergic diseases. RAPT plans to pursue development of RPT904 initially in food allergy and chronic spontaneous urticaria ("CSU").
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a consultant for the company. "We are pleased to welcome Lori as chair of the board," said Brian Wong, M.D., Ph.D., President and CEO of RAPT. "In the four years that Lori has served as a board membe
- RPT904 at both Q8W and Q12W dosing showed comparable efficacy and safety to omalizumab at Q4W dosing- Efficacy sustained at Week 16 after a single dose of RPT904- Well tolerated with no serious adverse events related to study drug- Jeyou to advance RPT904 to Phase 3 development in China- RAPT to discuss Phase 3 development path with FDA- RAPT to host conference call at 8:30 am ET today SOUTH SAN FRANCISCO, Calif. and SHANGHAI, Oct. 20, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunologica
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that the Company plans to report topline data from the Phase 2 clinical trial of RPT904 (JYB1904) in patients with Chronic Spontaneous Urticaria (CSU) conducted by its partner, Shanghai Jeyou Pharmaceutical Co., Ltd. (Jeyou), formerly called Shanghai Jemincare Pharmaceutical Co., Ltd., in a premarket press release and webcast on Monday, October 20, 2025.RAPT will host a webcast co
- RAPT obtains worldwide rights excluding China - - Jemincare receives $35 million upfront payment, up to $672.5 million in milestone payments and high single-digit to low-double digit royalties on future sales - - Jemincare is currently conducting Phase 2 trials in asthma and chronic spontaneous urticaria in China - - RAPT plans to initiate Phase 2b trial in food allergy next year - - RAPT to host a conference call at 8:30 a.m. ET - SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patient
SC 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)
SC 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)
SC 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)